false
0001468929
0001468929
2024-05-13
2024-05-13
0001468929
NXGL:CommonStockParValue0.001Member
2024-05-13
2024-05-13
0001468929
NXGL:WarrantsToPurchaseCommonStockMember
2024-05-13
2024-05-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 13, 2024
NEXGEL,
INC. |
(Exact
name of registrant as specified in its charter) |
Delaware |
|
001-41173 |
|
26-4042544 |
(State
or other jurisdiction |
|
(Commission |
|
(IRS
Employer |
of
incorporation) |
|
File Number) |
|
Identification
No.) |
2150
Cabot Boulevard West, Suite B
Langhorne,
Pennsylvania |
|
19067 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (215) 702-8550
(Former
name or former address, if changed since last report)
Not
Applicable
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 |
|
NXGL |
|
The
Nasdaq Capital Market LLC |
Warrants
to Purchase Common Stock |
|
NXGLW |
|
The
Nasdaq Capital Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
2.02 Results of Operations and Financial Condition
On
May 13, 2024, NexGel, Inc. (the “Company”) issued a press release reporting the Company’s results
for the quarter ended March 31, 2024, a copy of which is attached as Exhibit 99.1 hereto and is incorporated herein by reference.
The
information in Item 2.02 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is being furnished
and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), nor shall Exhibit 99.1 filed herewith be deemed incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
May 13, 2024 |
|
|
|
|
|
|
|
|
NEXGEL,
INC. |
|
|
|
|
|
|
By: |
/s/
Adam Levy |
|
|
|
Adam
Levy |
|
|
|
Chief
Executive Officer |
Exhibit
99.1
NEXGEL
Reports First Quarter 2024 Revenue of $1.27 Million, an Increase of 104% Year-Over-Year
LANGHORNE,
Pa. – May 13, 2024 – NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a
leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its
financial results for the first quarter ended March 31, 2024.
Adam
Levy, NEXGEL’s Chief Executive Officer, commented, “Following a record year of growth in 2023, I am pleased to report our
first quarter financial results that demonstrate steady growth year-over-year and preparedness for significant growth levers we expect
in 2024. Revenue for the quarter grew 104% year-over-year driven by growth in both contract manufacturing and consumer branded product
business segments of approximately 58% and 178%, respectively. In the first quarter and into the second quarter of this year we are investing
for the growth we expect in the back half of this year. We are nearly complete with the capacity expansion of our facility in Texas along
with installation of state-of-the art equipment in preparation for product launches with Abbvie and others. Additionally, we expect to
launch our first batch of consumer branded products in Europe and are in the final stages of receiving the proper certifications to do
so. We have a lot to be excited about regarding our future growth opportunities at NEXGEL.”
First
Quarter 2024 Financial Highlights
For
the quarter ended March 31, 2024, revenue totaled $1.27 million, an increase of $646,000, or 104%, as compared to $620,000 for the quarter
ended March 31, 2023. The increase in revenue was driven by sales growth in contract manufacturing of approximately 58% and branded products
of 178%.
Gross
profit totaled $277,000 for the three months ended March 31, 2024, compared to a gross profit loss of $57,000 for the three months ended
March 31, 2023. The increase of $334,000 in gross profit year-over-year was primarily due to the increase in consumer branded products.
Gross
profit margin for the first quarter of 2024 was 21.9% compared to a negative gross margin for the first quarter of 2023 of 9.2% and a
gross profit margin of 14.6% in the fourth quarter of 2023.
Cost
of revenues increased by $312,000, or 46.1%, to $989,000 for the three months ended March 31, 2024, as compared to $677,000 for the three
months ended March 31, 2023. The increase in cost of revenues is primarily aligned with the new product line growth and an increase in
compensation and benefits with the increase in revenue growth.
Selling,
general and administrative expenses increased by $349,000 or 43.8%, to $1.1 million for the three months ended March 31, 2024, as compared
to $797,000 for the three months ended March 31, 2023. The increase in selling, general and administrative expenses is primarily attributable
to an increase in advertising, marketing and Amazon fees, professional and consulting fees, and of compensation and benefits expense.
Research
and development expenses decreased by $27,000 to $2,000 for the three months ended March 31, 2024, from $29,000 for the three months
ended March 31, 2023.
Net
loss for the three months ended March 31, 2024, was $905,000 as compared to a net loss of 807,000 in the three months ended March
31, 2023.
As
of March 31, 2024, the Company had a cash balance of $2.4 million, which includes an approximate $1 million registered direct offering
led by insiders. During the quarter, there was a net usage of cash for investment due to several non-recurring key strategic investments
and acquisition costs.
As
of March 31, 2024, NEXGEL had 6,227,624 shares of common stock outstanding.
First
Quarter 2024 Financial Results Conference Call
Date:
May 13, 2024
Time:
4:30 P.M. ET
Live
Call: + 1-800-343-5419 (U.S. Toll Free) or + 1-203-518-9731 (International)
Webcast:
Events and Presentations
For
interested individuals unable to join the conference call, a replay will be available through May 27,
2024, by dialing + 1-844-512-2921 (U.S. Toll Free) or + 1-412-317-6671 (International). Participants must use the following code
to access the replay of the call: 11155952. An archived version of the webcast will also be available for 90 days.
About
NEXGEL, INC.
NEXGEL
is a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels.
Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. NEXGEL
brands include Silverseal, Hexagels, Turfguard, Kenkoderm, and Dermablock. Additionally, NEXGEL has strategic contract manufacturing
relationships with leading consumer healthcare companies.
Forward-Looking
Statement
This
press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part
of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words “believe,”
“anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,”
“prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,”
“should,” “would,” “may,” and “could,” are generally forward-looking in nature and not
historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the
Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or
achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements,
whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s
forward-looking statements, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, including
but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed
at http://www.sec.gov/.
Investor
Contacts:
Valter
Pinto, Managing Director
KCSA
Strategic Communications
212.896.1254
valter@kcsa.com
NEXGEL,
INC
CONDENSED
CONSOLIDATED BALANCE SHEETS
AS
OF MARCH 31, 2024 AND DECEMBER 31, 2023
(Unaudited)
(in
thousands, except share and per share data)
| |
March 31, 2024 | | |
December 31, 2023 | |
ASSETS: | |
| | | |
| | |
Current Assets: | |
| | | |
| | |
Cash | |
$ | 2,419 | | |
$ | 2,700 | |
Accounts receivable, net | |
| 739 | | |
| 633 | |
Inventory | |
| 1,369 | | |
| 1,319 | |
Prepaid expenses and other current assets | |
| 336 | | |
| 400 | |
Total current assets | |
| 4,863 | | |
| 5,052 | |
Goodwill | |
| 1,128 | | |
| 1,128 | |
Intangibles, net | |
| 302 | | |
| 326 | |
Property and equipment, net | |
| 2,194 | | |
| 1,499 | |
Operating lease - right of use asset | |
| 1,803 | | |
| 1,855 | |
Other assets | |
| 95 | | |
| 95 | |
Total assets | |
$ | 10,385 | | |
$ | 9,955 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,053 | | |
$ | 1,233 | |
Accrued expenses and other current liabilities | |
| 111 | | |
| 398 | |
Deferred revenue | |
| 250 | | |
| 20 | |
Current portion of note payable | |
| 87 | | |
| 80 | |
Warrant liability | |
| 255 | | |
| 146 | |
Contingent consideration liability | |
| 439 | | |
| 439 | |
Financing lease liability, current portion | |
| 55 | | |
| - | |
Operating lease liabilities, current portion | |
| 233 | | |
| 233 | |
Total current liabilities | |
| 2,483 | | |
| 2,549 | |
Operating lease liabilities, net of current portion | |
| 1,682 | | |
| 1,727 | |
Financing lease liability, net of current portion | |
| 352 | | |
| - | |
Notes payable, net of current portion | |
| 663 | | |
| 513 | |
Total liabilities | |
| 5,180 | | |
| 4,789 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 15) | |
| - | | |
| - | |
| |
| | | |
| | |
Preferred stock, par value $0.001 per share, 5,000,000 shares authorized, no shares issued and outstanding | |
| - | | |
| - | |
Common stock, par value $0.001 per share, 25,000,000 shares authorized; 6,227,624 and 5,741,838 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | |
| 6 | | |
| 6 | |
Additional paid-in capital | |
| 20,350 | | |
| 19,406 | |
Accumulated deficit | |
| (15,568 | ) | |
| (14,715 | ) |
Total NexGel stockholders’ equity | |
| 4,788 | | |
| 4,697 | |
Non-controlling interest in joint venture | |
| 417 | | |
| 469 | |
Total stockholders’ equity | |
| 5,205 | | |
| 5,166 | |
Total liabilities and stockholders’ equity | |
$ | 10,385 | | |
$ | 9,955 | |
NEXGEL,
INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
FOR
THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(Unaudited)
(in
thousands, except share and per share data)
| |
Three months ended | |
| |
March 31, | |
| |
2024 | | |
2023 | |
Revenues, net | |
$ | 1,266 | | |
$ | 620 | |
| |
| | | |
| | |
Cost of revenues | |
| 989 | | |
| 677 | |
| |
| | | |
| | |
Gross margin (loss) | |
| 277 | | |
| (57 | ) |
| |
| | | |
| | |
Operating expenses | |
| | | |
| | |
Research and development | |
| 2 | | |
| 29 | |
Selling, general and administrative | |
| 1,146 | | |
| 797 | |
Total operating expenses | |
| 1,148 | | |
| 826 | |
| |
| | | |
| | |
Loss from operations | |
| (871 | ) | |
| (883 | ) |
| |
| | | |
| | |
Other income (expense) | |
| | | |
| | |
Interest income (expense), net | |
| (15 | ) | |
| (1 | ) |
Changes in fair value of warrant liability and warrant modification expense | |
| (53 | ) | |
| 66 | |
Gain on investment in marketable securities | |
| 34 | | |
| 7 | |
Other income | |
| — | | |
| 4 | |
Total other income (expense), net | |
| (34 | ) | |
| 76 | |
Loss before income taxes | |
| (905 | ) | |
| (807 | ) |
Income tax expense | |
| — | | |
| — | |
Net loss | |
| (905 | ) | |
| (807 | ) |
Less: Income (loss) attributable to non-controlling interest in joint venture | |
| (52 | ) | |
| 7 | |
Net loss attributable to NexGel stockholders | |
$ | (853 | ) | |
$ | (814 | ) |
Net loss per common share - basic | |
$ | (0.14 | ) | |
$ | (0.15 | ) |
Net loss per common share - diluted | |
$ | (0.14 | ) | |
$ | (0.15 | ) |
Weighted average shares used in computing net loss per common share - basic | |
| 5,982,062 | | |
| 5,586,326 | |
Weighted average shares used in computing net loss per common share – diluted | |
| 5,982,062 | | |
| 5,586,326 | |
NEXGEL,
INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR
THE THREE MONTHS ENDED MARCH 31, 2024 AND 2023
(Unaudited)
(in
thousands)
| |
Three Months Ended March 31, | |
| |
2024 | | |
2023 | |
Operating Activities | |
| | | |
| | |
Net loss | |
$ | (853 | ) | |
$ | (814 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Income (loss) attributable to non-controlling interest in joint venture | |
| (52 | ) | |
| 7 | |
Depreciation and amortization | |
| 62 | | |
| 31 | |
Share-based compensation and restricted stock vesting | |
| 54 | | |
| 24 | |
Gain on investment in marketable securities | |
| (34 | ) | |
| 7 | |
Changes in fair value of warrant liability | |
| 53 | | |
| (66 | ) |
Amortization of right of use asset | |
| 52 | | |
| 49 | |
| |
| | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (106 | ) | |
| (158 | ) |
Inventory | |
| (50 | ) | |
| (466 | ) |
Prepaid expenses and other assets | |
| 64 | | |
| 11 | |
Accounts payable | |
| (180 | ) | |
| 722 | |
Accrued expenses and other current liabilities | |
| (287 | ) | |
| (18 | ) |
Deferred revenue | |
| 230 | | |
| — | |
Operating lease liability | |
| (45 | ) | |
| (38 | ) |
Net Cash Used in Operating Activities | |
| (1,092 | ) | |
| (709 | ) |
| |
| | | |
| | |
Investing Activities | |
| | | |
| | |
Proceeds from sales of marketable securities | |
| 34 | | |
| 485 | |
Capital expenditures | |
| (152 | ) | |
| (88 | ) |
Net Cash Provided by (Used in) Investing Activities | |
| (118 | ) | |
| 397 | |
| |
| | | |
| | |
Financing Activities | |
| | | |
| | |
Proceeds from rights offering, net of expenses | |
| 946 | | |
| — | |
Principal payment on financing lease liability | |
| (9 | ) | |
| — | |
Principal payments of notes payable | |
| (8 | ) | |
| (2 | ) |
Net Cash Provided by (Used in) Financing Activities | |
| 929 | | |
| (2 | ) |
Net Decrease in Cash | |
| (281 | ) | |
| (314 | ) |
Cash – Beginning of period | |
| 2,700 | | |
| 1,101 | |
Cash – End of period | |
$ | 2,419 | | |
$ | 787 | |
Supplemental Disclosure of Cash Flows Information | |
| | | |
| | |
Cash paid during the year for: | |
| | | |
| | |
Interest | |
$ | 10 | | |
$ | — | |
Taxes | |
$ | — | | |
$ | — | |
| |
| | | |
| | |
Supplemental Non-cash Investing and Financing activities | |
| | | |
| | |
Property and equipment financed under notes payable | |
$ | 165 | | |
$ | — | |
Property and equipment financed under financing leases | |
$ | 416 | | |
$ | — | |
Property and equipment contributed as capital investment to JV | |
$ | — | | |
$ | 500 | |
ROU asset and operating lease liabilities recognized upon consolidation of JV | |
$ | — | | |
$ | 334 | |
v3.24.1.1.u2
Cover
|
May 13, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
May 13, 2024
|
Entity File Number |
001-41173
|
Entity Registrant Name |
NEXGEL,
INC.
|
Entity Central Index Key |
0001468929
|
Entity Tax Identification Number |
26-4042544
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2150
Cabot Boulevard West
|
Entity Address, Address Line Two |
Suite B
|
Entity Address, City or Town |
Langhorne
|
Entity Address, State or Province |
PA
|
Entity Address, Postal Zip Code |
19067
|
City Area Code |
(215)
|
Local Phone Number |
702-8550
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.001 |
|
Title of 12(b) Security |
Common
Stock, par value $0.001
|
Trading Symbol |
NXGL
|
Security Exchange Name |
NASDAQ
|
Warrants to Purchase Common Stock |
|
Title of 12(b) Security |
Warrants
to Purchase Common Stock
|
Trading Symbol |
NXGLW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=NXGL_CommonStockParValue0.001Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=NXGL_WarrantsToPurchaseCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
NexGel (NASDAQ:NXGLW)
過去 株価チャート
から 4 2024 まで 5 2024
NexGel (NASDAQ:NXGLW)
過去 株価チャート
から 5 2023 まで 5 2024